Journal of the American Society of Nephrology
2008 JASN IMPACT FACTOR 7.505 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on April 23, 2009
J Am Soc Nephrol 20: 1264-1274, 2009
© 2009 American Society of Nephrology
doi: 10.1681/ASN.2008060572

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2008060572v1
20/6/1264    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Westenfeld, R.
Right arrow Articles by Jahnen-Dechent, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Westenfeld, R.
Right arrow Articles by Jahnen-Dechent, W.
Related Collections
Right arrowRelated Articles

BASIC RESEARCH

Fetuin-A Protects against Atherosclerotic Calcification in CKD

Ralf Westenfeld*, Cora Schäfer{dagger}, Thilo Krüger*, Christian Haarmann*, Leon J. Schurgers{ddagger}, Chris Reutelingsperger{ddagger}, Ognen Ivanovski§, Tilman Drueke§, Ziad A. Massy||, Markus Ketteler, Jürgen Floege* and Willi Jahnen-Dechent{dagger}

Departments of * Nephrology and {dagger} Biomedical Engineering, Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen University Hospital, Aachen, and Department of Nephrology, Klinikum Coburg GmbH, Coburg, Germany; {ddagger} Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht, Netherlands; and § INSERM Unit 845, Necker Hospital, Paris, and || Inserm ERI-12 and University of Picardie Jules Verne and Amiens University Hospital, Amiens, France

Correspondence: Dr. Willi Jahnen-Dechent, Department of Biomedical Engineering, Biointerface Group, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074 Aachen, Germany. Phone: +49-241-80-80163; Fax: +49-241-80-82573; E-mail: willi.jahnen{at}rwth-aachen.de

Received for publication June 5, 2008. Accepted for publication January 19, 2009.

Reduced serum levels of the calcification inhibitor fetuin-A associate with increased cardiovascular mortality in dialysis patients. Fetuin-A–deficient mice display calcification of various tissues but notably not of the vasculature. This absence of vascular calcification may result from the protection of an intact endothelium, which becomes severely compromised in the setting of atherosclerosis. To test this hypothesis, we generated fetuin-A/apolipoprotein E (ApoE)-deficient mice and compared them with ApoE-deficient and wild-type mice with regard to atheroma formation and extraosseous calcification. We assigned mice to three treatment groups for 9 wk: (1) Standard diet, (2) high-phosphate diet, or (3) unilateral nephrectomy (causing chronic kidney disease [CKD]) plus high-phosphate diet. Serum urea, phosphate, and parathyroid hormone levels were similar in all genotypes after the interventions. Fetuin-A deficiency did not affect the extent of aortic lipid deposition, neointima formation, and coronary sclerosis observed with ApoE deficiency, but the combination of fetuin-A deficiency, hyperphosphatemia, and CKD led to a 15-fold increase in vascular calcification in this model of atherosclerosis. Fetuin-A deficiency almost exclusively promoted intimal rather than medial calcification of atheromatous lesions. High-phosphate diet and CKD also led to an increase in valvular calcification and aorta-associated apoptosis, with wild-type mice having the least, ApoE-deficient mice intermediate, and fetuin-A/ApoE-deficient mice the most. In addition, the combination of fetuin-A deficiency, high-phosphate diet, and CKD in ApoE-deficient mice greatly enhanced myocardial calcification, whereas the absence of fetuin-A did not affect the incidence of renal calcification. In conclusion, fetuin-A inhibits pathologic calcification in both the soft tissue and vasculature, even in the setting of atherosclerosis.


Related Articles

Finding New Sea Legs for Urine Proteomics
Eric G. Neilson
J. Am. Soc. Nephrol. 2009 20: 1162. [Full Text] [PDF]

Vascular Calcification: The Three-Hit Model
Sharon M. Moe
J. Am. Soc. Nephrol. 2009 20: 1162-1164. [Full Text] [PDF]



This article has been cited by other articles:


Home page
J. Am. Soc. Nephrol.Home page
S. M. Moe
Vascular Calcification: The Three-Hit Model
J. Am. Soc. Nephrol., June 1, 2009; 20(6): 1162 - 1164.
[Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP